The Signature Keynote
The Million Dollar Patient
One patient. Eighteen years of treatment. More than $1.4 million in treatment costs. And the interventions that reduced his annual treatment cost to zero.
$1.4M+
Total treatment spend
$0
Annual cost today
18 yrs
Treatment timeline
Cumulative plan spend
$0
$0 / year
2005 · chapter 1 of 6
Keep scrolling — watch the meter run
2005
The diagnosis
At 28, Matt went from fully healthy to numb from the waist down and unable to walk. Relapsing-Remitting Multiple Sclerosis. The meter hadn’t started running yet — but it was about to.
2007–2017
A decade of Tysabri
Monthly infusions at roughly $90,000 a year. Ten years of them. Nobody ever sat down and asked whether there was a better way — the claims just kept paying.
2017–2022
Ocrevus, and a first intervention
A switch to Ocrevus at $80,000 a year. The first clinical intervention shaved $10,000 a year off the cost — the first time anyone treated the file like a story instead of a line item.
2023–2024
Therapeutic interchange
Mavenclad, at $60,000 a year. Therapeutic interchange saved another $20,000 annually — and set up something almost no specialty patient ever reaches.
2025
Deprescribed
After nearly two decades on specialty therapy, Matt’s care team deprescribed entirely. The number stopped moving. Twenty years of MS — and the annual cost of therapy today is zero.
2026 +
The lesson
His health plan spent $1.4 million. It didn’t have to be that much. High-cost claims aren’t line items — they’re stories with interventions waiting to be made. That’s the keynote.
$1.4M spent. $0 today.
The numbers at a glance
| Period | Treatment | Annual Cost | Total Spend | Intervention | Plan Savings |
|---|---|---|---|---|---|
| 2007-2017 | Tysabri infusion therapy | $90,000 | $900,000 | -- | -- |
| 2017-2022 | Ocrevus infusion therapy | $80,000 | $400,000 | Clinical Intervention | $10,000/yr |
| 2023-2024 | Mavenclad therapy | $60,000 | $120,000 | Therapeutic Interchange | $20,000/yr |
| 2025 | Deprescribed | $0 | $0 | Deprescribing | $60,000/yr |
| 2026+ | Off therapy | $0 | $0 | Avoided Spend | $60,000/yr |
Behind the numbers
In 2005, Matt Cavallo was diagnosed with relapsing-remitting multiple sclerosis. What followed was nearly two decades of specialty drug therapy, beginning with Tysabri infusions at $90,000 per year, continuing through Ocrevus and Mavenclad, and ultimately reaching a place few specialty patients do: deprescribed entirely.
Along the way, his health plan spent more than $1.4 million on his care. It did not have to be that much. Earlier clinical intervention, therapeutic interchange, and ultimately deprescribing generated tens of thousands of dollars in annual savings while keeping the focus on the patient.
This case study is not only about one patient. It shows what can happen when health systems, payers, and employers stop treating high-cost claims as line items and start seeing them as stories with opportunities for intervention.
Want Matt to tell this story to your audience?
The Million Dollar Patient is available as a keynote, workshop, webinar, or podcast conversation for health systems, payers, employers, and anyone responsible for pharmacy cost and member outcomes.
Book This Keynote